北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance
作者: Jiang, Qian; Qin, Ya-Zhen; Lai, Yue-Yun; Jiang, Hao; Wang, Jing; Huang, Xiao-Jun
关键词: BCR-ABL ; mutation ; chronic myeloid leukemia ; dasatinib ; nilotinib ; imatinib
刊名: LEUKEMIA & LYMPHOMA
发表日期: 2015-07-01
DOI: 10.3109/10428194.2014.982639
卷: 56, 期:7, 页:2075-2081
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Hematology
研究领域[WOS]: Oncology ; Hematology
关键词[WOS]: CHRONIC MYELOID-LEUKEMIA ; ABL KINASE DOMAIN ; CHRONIC MYELOGENOUS LEUKEMIA ; ACUTE LYMPHOBLASTIC-LEUKEMIA ; NILOTINIB FORMERLY AMN107 ; GIMEMA WORKING PARTY ; IMATINIB-RESISTANT ; CHRONIC-PHASE ; ACCELERATED-PHASE ; BLAST CRISIS
英文摘要:

The treatment outcome and development of new mutations in patients with imatinib- and/or nilotinib-failure Philadelphia chromosome positive (Ph+) leukemia with highly nilotinib-resistant mutations (Y253H, E255K/V and F359V/C) were assessed on dasatinib therapy. A total of 111 patients with Ph+ leukemia were grouped into three cohorts by baseline BCR-ABL kinase domain mutation status: no mutation (n = 44), non-nilotinib-resistant mutations (n = 26) or nilotinib-resistant mutations (n = 41). The frequencies of hematological, cytogenetic and molecular responses and clinical resistance to dasatinib were similar among the three cohorts during dasatinib therapy. In dasatinib-resistant patients, new mutations were most frequently observed in the cohort with nilotinib-resistant mutations (p = 0.001). Multivariate analysis revealed that advanced disease and harboring Y253H or F359V mutation before dasatinib were independent predictors of developing new mutations. We conclude that patients with Ph+ leukemia with Y253H or F359V mutation have a high likelihood of developing new mutations in the setting of dasatinib resistance.

语种: 英语
所属项目编号: Z131100004013026
项目资助者: Beijing Municipal Science &amp ; Technology Commission
WOS记录号: WOS:000359888700025
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/58495
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Inst Hematol, Peoples Hosp, Beijing 100044, Peoples R China

Recommended Citation:
Jiang, Qian,Qin, Ya-Zhen,Lai, Yue-Yun,et al. Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance[J]. LEUKEMIA & LYMPHOMA,2015,56(7):2075-2081.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Jiang, Qian]'s Articles
[Qin, Ya-Zhen]'s Articles
[Lai, Yue-Yun]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Jiang, Qian]‘s Articles
[Qin, Ya-Zhen]‘s Articles
[Lai, Yue-Yun]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace